<DOC>
	<DOCNO>NCT00377078</DOCNO>
	<brief_summary>Primary objective pilot study evaluate effect recombinant human lactoferrin rate infection Clostridium difficile long-term care patient support enteral feeding require broad spectrum antibiotic .</brief_summary>
	<brief_title>Use Recombinant Human Lactoferrin Long-Term Care Patients With Feeding Tubes With Clostridium Difficile .</brief_title>
	<detailed_description>This study prospective , randomize , double blind , placebo control comparison . Product test : Lactoferrin ( human ) derive rice . Amount , dosage , route administration , duration : Subjects receive 3 gram lactoferrin every 24 hour flush solution automate enteric feeding system . Dosing begin antibiotic dosing continue 8 week follow initial dose antibiotic . If change/adjustment antibiotic initiation another course antibiotic therapy study period , blood stool sample take additional study point , extension 8 week study material administration . Objectives : To test use lactoferrin ( human ) derive rice management post-antibiotic colonization Clostridium difficile result inflammation reaction intestine long-term care patient enteral feeding . Clinical Endpoints : C. difficile antigen status change Diarrhea ( 2 loose stool , conform container , 24 hour ) Clinical Markers : C. difficile toxin status change Stool serum proinflammatory anti-inflammatory cytokine 1 antitrypsin serum stool cRP - serum WBC - blood Study Groups : All patient enteral feed gastrostomy , naso-gastric , jejunostomy tube . At first antibiotic treatment ( start study ) , subject randomize study treatment Test : Recombinant human lactoferrin rice 50 mM NaCl enteral feeding flush . 5 mg/mL lactoferrin 600 mL 0.3 % ( 50 mM ) saline administer every 24 hour 8 week study period . Controls : 600 mL 0.3 % ( 50 mM ) saline All material test control flush fluid supply Ventria Bioscience container label patient study number , enteral feeding system flush , expiration date sponsor name . Codes hold Ventria broken 30 patient complete . A sealed copy code available principal investigator . In case adverse event code break request principal investigator . Preparation : One bottle flush solution powder dissolve 600 mL water . The 600 mL flush use 24 hour period automatic flush standard enteral feeding pump use . If flush material remain end cycle , administer bolus dose less 200 mL . Subjects : Thirty patient enrol intent treat mask , randomize , placebo control study . All subject long-term care facility Johns Hopkins Bayview Medical Center . Inclusion Criteria - Patients long-term care facility , Ventilator Rehabilitation Unit ( VRU ) ( Plaza ) John Burton Care Center Johns Hopkins Bayview Medical Center . - Nutrition via gastrostomy , naso-gastric jejunostomy enteral feeding system . - Patients supplemental oral intake , primary nutrition via gastrostomy/jejunostomy tube . - Patients colostomy also allow - Not currently antibiotic therapy antibiotic within 10 day . - Patient negative Clostridium difficile antigen screen - Patient , guardian health care agent willing give inform consent . Exclusion Criteria - Patients receive vancomycin , linezolid , metronidazole antibiotic treatment , broad spectrum antibiotic . All antibiotic qualify . - Patients illeostomies . - Patients sign symptom C. difficile infection ; diarrhea ( two liquid stool 24-hour period ) elevate WBC ( 15,000/mm3 ) . - Known allergy rice rice product . Additionally , principal investigator may declare patient ineligible severity illness may limit adequate time follow-up data collection . Study Procedures : All patient ( new current antibiotic treatment free 10 day ) negative C. difficile VRU John Burton Care Center enteral feeding invite participate study . New patient screen C. difficile part admit procedure ; current patient screen current C. difficile antigen status . Patients guardian patient interested participation ask sign inform consent . When patient require first treatment broad spectrum antibiotic , randomize study . Study material administer via flush cycle enteral feeding system . The typical daily flush 600 mL dilute saline . The study material one third normal saline , approximately 0.3 % 50 mM without lactoferrin . The recombinant human lactoferrin rice 5 mg/mL . Study material use flush cycle , 600 mL per day , begin first day antibiotic treatment 8 week follow final dose antibiotic . At entry study , patient blood stool sample take assay : C. difficile antigen toxin C. difficile bacterial culture , aliquot stool recover organism frozen future analysis . Serum stool cytokine cRP – c reactive protein - blood 1 antitrypsin stool blood White blood cell count differential Patients positive C. difficile antigen time zero exit study consider intent treat analysis . Samples take assay marker two six week start antibiotic treatment , 8 week post antibiotic initiation exit study period . A stool sample collect weekly , addition regular study time point . This sample frozen future analysis . Patients monitor daily study occurrence diarrhea throughout study period . The definition diarrhea stool flow shape container . If second course antibiotic require 8 week post antibiotic period , sample take assay study marker time study course continue , extend . Patients become positive C. difficile remain study require treatment C. difficile . At initiation treatment C. difficile , study sample collect patient exit study , include analysis . Patients C. difficile antigen positive remain study positive test C. difficile toxin A B confirmed . Statistical Analyses : Data summarize number percent patient convert negative positive C. difficile antigen number percent patient report diarrhea time . The number day subject diarrhea-free 8-week study period also record . These data analyze comparison rate use Fisher ’ Exact Test 95 % confidence interval . Due small number subject study , goal identify trend rather statistical significance</detailed_description>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Patients longterm care facility , Ventilator Rehabilitation Unit ( VRU ) ( Plaza ) John Burton Care Center Johns Hopkins Bayview Medical Center . Nutrition via gastrostomy , nasogastric jejunostomy enteral feeding system . Patients supplemental oral intake , primary nutrition via gastrostomy/jejunostomy tube . Patients colostomy also allow Not currently antibiotic therapy antibiotic within 10 day . Patient negative Clostridium difficile antigen screen Patient , guardian health care agent willing give inform consent . Patients receive vancomycin , linezolid , metronidazole antibiotic treatment , broad spectrum antibiotic . All antibiotic qualify . Patients illeostomies . Patients sign symptom C. difficile infection ; diarrhea ( two liquid stool 24hour period ) elevate WBC ( 15,000/mm3 ) . Known allergy rice rice product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>recombinant human lactoferrin</keyword>
</DOC>